This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Cara Therapeutics stock in Canada | $13.93

Own Cara Therapeutics shares in just a few minutes.

Posted

Fact checked

Cara Therapeutics, Inc is a biotechnology business based in the US. Cara Therapeutics shares (CARA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.93 – an increase of 1.53% over the previous week. Cara Therapeutics employs 76 staff and has a trailing 12-month revenue of around $27.5 million.

How to buy shares in Cara Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: CARA in this case.
  5. Research Cara Therapeutics shares. The platform should provide the latest information available.
  6. Buy your Cara Therapeutics shares. It's that simple.

How has Coronavirus impacted Cara Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Cara Therapeutics's share price has had significant negative movement.

Its last market close was $13.93, which is 19.15% down on its pre-crash value of $17.23 and 56.87% up on the lowest point reached during the March crash when the shares fell as low as $8.88.

If you had bought $1,000 worth of Cara Therapeutics shares at the start of February 2020, those shares would have been worth $678.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $854.05.

Cara Therapeutics share price

Use our graph to track the performance of CARA stocks over time.

Cara Therapeutics shares at a glance

Information last updated 2020-12-02.
Latest market close $13.93
52-week range $8.88 - $18.32
50-day moving average $14.4234
200-day moving average $15.5581
Wall St. target price $32.63
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.166

Compare online trading platforms

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Buy and sell thousands of US and Canadian stocks and ETFs commission-free with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, Mutual Funds, ETFs, Currencies, Futures, Precious Metals
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are equal to or greater than US$10.00)
Min. $1.00, Max. 0.5% of trade value
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, IPOs, Precious Metals
$4.95 - $9.95
$9.95 + $1 per contract
$0
Free
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
loading

Compare up to 4 providers

Name Product Minimum deposit to invest Funding methods Management fee Available asset types
CI Direct Investing (formerly WealthBar)
$1,000
Direct deposit, Bank transfer
0.35% - 0.60%
Mutual Funds, ETFs
CI Direct Investing offers access to an exclusive and personalized investment portfolio. Get up to $10,000 managed free for a year when you sign up for your first CI Direct Investing account and fund your account.
Moka
$0
Automatic bank withdrawals
$3/month
ETFs
The Moka app rounds up every purchase you make to the nearest dollar and invests the spare change into low-cost exchange-traded funds (ETFs).
Justwealth
$5,000
Direct deposit, Bank transfer, Automatic bank withdrawals
0.50%
ETFs
Receive a cash bonus of $50.00-$225.00 when you open a new Justwealth account. RESP accounts require no minimum deposit to begin investing.
Wealthsimple Invest
$1
Direct deposit, Bank transfer
0.40% - 0.50%
Stocks, Bonds, ETFs, Commodities
Get a $50 bonus when you open and fund your first Wealthsimple Invest account with a minimum initial deposit of at least $500. Trade and Cash accounts are not eligible.
loading

Compare up to 4 providers

Name Product Minimum Opening Deposit Commission Available Markets Platforms
Forex.com
US$100
Minimum US$25
Forex
Metals
Commodities
Indices
Shares
Forex.com Desktop, Forex.com Web Trading, Forex.com Mobile Trading, MetaTrader 4
CFDs are leveraged products which involves greater risk than using cash resources only. You could lose all or more of your initial investment. Trade 80+ currency pairs and 220+ CFDs in equities, commodities and indices on Forex.com.
loading

Compare up to 4 providers

Is it a good time to buy Cara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cara Therapeutics price performance over time

Historical closes compared with the last close of $13.93

1 week (2020-11-27) -6.82%
1 month (2020-11-05) 0.29%
3 months (2020-09-04) -8.60%
6 months (2020-06-05) -9.37%
1 year (2019-12-05) -13.64%
2 years (2018-12-04) -21.57%
3 years (2017-12-05) 11.62%
5 years (2015-12-04) -2.66%

Cara Therapeutics financials

Revenue TTM USD$27.5 million
Gross profit TTM USD$-93,934,000
Return on assets TTM -31.29%
Return on equity TTM -58.34%
Profit margin 0%
Book value $2.726
Market capitalisation USD$732 million

TTM: trailing 12 months

How to short and sell Cara Therapeutics shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "CARA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.8 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 0.1% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.

Cara Therapeutics's "short interest ratio" (SIR)

Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 443268.75). Cara Therapeutics's SIR currently stands at 8.64. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 8640 shares are currently held short.

However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0871% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 87 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.

Find out more about how you can short Cara Therapeutics stock.

Cara Therapeutics share dividends

We're not expecting Cara Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Cara Therapeutics's shares ever split?

Cara Therapeutics's shares were split on a 1:2 basis on 16 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.

Cara Therapeutics share price volatility

Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as $8.88 up to $18.32. A popular way to gauge a stock's volatility is its "beta".

CARA.US volatility(beta: 1.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.7717. This would suggest that Cara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cara Therapeutics overview

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site